Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR (Tacrolimus).
The study is designed to facilitate expanded access of Envarsus XR treatment to renal transplant patients. Patients are identified by the site investigator as a patient who has experienced favorable outcomes while in an Envarsus XR (LCP-Tacro) clinical study and/or the site investigator has identified a renal transplant patient with a medical need for an alternative tacrolimus treatment versus the patient's current tacrolimus treatment.
Study Type
EXPANDED_ACCESS
Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.